FIELD: medicine, pharmaceutics.
SUBSTANCE: invention describes poly(ADP-riboso)polymerase inhibitors of formula (Ik) its pharmaceutically acceptable salt wherein R101, R104 and R105 represent H; R102 represents R11 wherein R11 is specified from pyrrolidinyl, oxazolyl, imidazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl and azepanyl with R102 being substituted by one or two (O) substitutes; R103 represents fluorine, besides, a pharmaceutical composition on the basis of said compounds showing poly(ADP-riboso)polymerase (PARP) inhibitory activity, a method of treating cancer and a method of reducing tumour volume in a mammal.
EFFECT: there are produced and described new compounds which show poly(ADP-riboso)polymerase (PARP) inhibitory activity.
9 cl, 491 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
5-HT RECEPTOR MODULATORS AND METHODS FOR USING THEM | 2010 |
|
RU2542103C2 |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
AZAADAMANTANE DERIVATIVES AND METHODS FOR APPLYING | 2007 |
|
RU2450002C2 |
NOVEL 4-AMINO-N-HYDROXYBENZAMIDES AS HDAC INHIBITORS FOR TREATING CANCER | 2012 |
|
RU2591190C2 |
DERIVATIVES OF PIPERIDINE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2298550C2 |
CONDENSED PYRIDAZINE DERIVATIVES AND DRUGS HAVING THE COMPOUNDS AS ACTIVE INGREDIENTS | 2003 |
|
RU2292337C2 |
HETEROCYCLIC COMPOUNDS, THEIR USING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF STATES MEDIATED BY CXCR4 AND CCR5 | 2001 |
|
RU2277092C2 |
NOVEL COMPOUNDS | 2001 |
|
RU2419608C2 |
OXAZOLE DERIVATIVES SUBSTITUTED WITH CARBOXYLIC ACIDS AS PPAR-ALPHA AND PPAR-GAMMA ACTIVATORS IN DIABETES TREATMENT | 2002 |
|
RU2278859C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
Authors
Dates
2012-07-10—Published
2007-12-20—Filed